By accessing this site, you accept the Terms of Use and Privacy Policy. Sorry, Leafly isn’t available in your location yet. After ten hours of testimony about cannabidiol (CBD) from more than 100 stakeholders, two things are clear: The American public has a high desire for CBD products, and too many CBD manufacturers are delivering shoddy goods. On Friday, FDA Acting Commissioner Ned Sharpless kicked off the agency’s historic first-ever public hearing on CBD by noting that “we’ve seen an explosion of interest in products including CBD, [but] there is much we don’t know.” There’s plenty we do know, however, and many of those facts were aired at the hearing, which Leafly’s editors Bruce Barcott, David Downs, and Ben Adlin covered live as it happened. At the end of the day, here are our consensus takeaways. One of the most constant themes in today’s hearing: The current CBD market is flooded with sketchy players selling junk products. 5 Takeaways From the FDA’s Hearing on CBD
thumbnail courtesy of leafly.com
Leave a Reply